Survodutide

Dual GLP-1 / glucagon agonist (Boehringer Ingelheim / Zealand) — studied for weight loss and NASH.

Survodutide is another GLP-1/glucagon dual agonist, from Boehringer Ingelheim and Zealand. Its standout feature is what the glucagon arm does to body composition: in the Phase 3 SYNCHRONIZE-1 trial it produced ~16.6% weight loss while preferentially burning fat and sparing lean mass — a benefit pure GLP-1 drugs don't share. It's also a leading candidate for liver disease, with dedicated Phase 3 MASH trials (LIVERAGE) reading out in 2026. Still investigational for now.

Dose

Weekly titration.

Reconstitute

Standard.

Schedule

Weekly.

Half-life

~5–7 days.

Timing

Same day each week.

Risks

GI side effects. Emerging.

Educational reference — not medical advice. Many peptides are not approved for the uses discussed; verify status in your jurisdiction and decide anything here with a qualified clinician.

within Weight Loss & GLP Class